

Representation of Activities Preparatory to Research (RAPtoR)

Requestor	's Name:	Department & Location:		
Telephone	:	Email Address:		
Please specify the date by which PRELIMINARY DATA is needed:				
	sentation is valid for six months following that the following the after that date, another RAPtoR will be required	he date upon which this RAPtoR is executed. If further review is		
restriction select the To develop To dete		criteria		
		Information (PHI) data that will be examined in this ary PHI to meet your needs—as required by HIPAA:		
C. In a fev	w sentences, please describe the reason	n for which the researcher plans to examine data:		
Does any If Yes, plea	ON TO USE DECEDENT PHI of the data to be collected include PHI of dase answer the following questions. to the ACKNOWLEDGEMENT & ATTESTAT			
	access PHI of decedents, the following three renat the statement is true.	presentations must be TRUE. Use the checkbox below to		
☐ TRUE ☐ TRUE ☐ TRUE ☐ TRUE	subjects). The PHI that is being requested is necessary	on decedents (not to be compared with PHI of living human y for the research purposes.		
	will be viewed by an individual, not on KPMAS re ntact Chanika Nelson (chanika.m.nelson@kp.org	egion's workforce, Privacy Rule disclosure accounting rules) for instructions.		
• PHI 🗆	will or □ will NOT be viewed by an individual((s) who is not on KPMAS region's workforce.		

1

If PHI will be viewed by an individual(s) who is not on KPMAS region's workforce, will the data of more than 49

individuals be viewed? \square Yes or \square No

ACKNOWLEDGEMENTS & ATTESTATIONS

I acknowledge that the HIPAA Privacy Rule imposes restrictions on the use of PHI in activities preparatory to research, defined as the:

• Development of research questions,

permission is granted to access PHI as described above [B].

- Determination of study feasibility (in terms of the available number and eligibility of potential study participants),
- Development of eligibility (inclusion and exclusion) criteria, and
- Determination of eligibility for study participation of individual potential subjects.

I, therefore, attest that:

- 1. I will use only the PHI that is necessary to prepare a research protocol for grant preparation, IRB review, and/or for those preparatory to research activities listed above [B].
- 2. I will not remove any PHI, abstracted in the course of my review of PHI from Kaiser Foundation Health Plan of the Mid-Atlantic States and the Mid-Atlantic Permanente Medical Group entities under the HIPAA Privacy Rule.
- 3. I will not disclose the abstracted PHI under any circumstances to anyone outside of these covered entities.
- 4. I will apply the above conditions to PHI maintained by the Kaiser Foundation Health Plan of the Mid-Atlantic and the Mid-Atlantic Permanente Medical Group covered entities.

Signature	Printed Name	Date
You will be notified if the Privacy Rule requing nay be required to file a revised attestation		ge in these requirements occurs, you
Submit a signed and dated copy of this form	to your department, section, center, or in	nstitute administrator and the original
	nente Research Institute (MAPRI) Privacj nente Medical Group	y Officer for Research
2101 East Jefferson	n Street, 3 West	
Rockville, MD 2085 Chanika.M.Nelson		
Approval:		

Please allow 7 business days for the processing and approval of this document.

Frequently Asked Questions: Reviews Preparatory to Research

- 1. Q: 45 CFR Parts 160 and 164 under "Permitted uses and disclosures (reviews preparatory to research)", states "No protected health information is to be removed from the covered entity by the researcher in the course of the review." What is specifically not permitted to be removed from the building?
 - A: The HIPAA privacy regulations say that the information cannot be removed from the building. In addition to prohibiting physical records of PHI from removal, this means that copying information and then removing the copied information is also prohibited, which includes electronic copies of the records.
- 2. Q: At what point do activities "preparatory to research" cross over to "research", such as asking questions from the patient to see if they are eligible versus having patients sign a release of medical information so that you can look through their medical records to see if they are eligible?
 - A: Activities prior to interactions with the potential subject (for example chart review to obtain names for screening) would be acceptable under Preparatory to Research. Once the contact is made, however, further information provided through interviews, tests or record reviews would be considered "screening procedures" that would be part of conducting the research and would require IRB approval.
- 3. Q: I am getting access to PHI from another covered entity under the 'preparatory to research' rule. I have provided the other facility with a written representation as they require. Do I need to track disclosures?
 - A: You do not need to track the disclosures, but the other facility does. Disclosures (release of information outside a covered entity) made under representations (reviews preparatory to research or decedent research), as well as disclosures made under waivers, require tracking. So most likely you will have to satisfy the requirements established by that covered entity for tracking.
- 4. Q: Is a review preparatory to research considered a disclosure or use by a covered entity under HIPAA?
 - A: A "use" is when the PHI is accessed by someone within KP; a "disclosure" is when the PHI is accessed by someone outside our covered entity. Only disclosures that are made without permission are subject to "disclosure accounting". Uses of PHI by the covered entity are not required to be tracked for accounting purposes. So if you do a preparatory to research activity and all you do falls under "use", no tracking is needed. If, however, you do any "disclosure" under that preparatory activity, then that would have to be tracked.
- 5. Q: If, during the review of data, I find a viable research question, may I begin to establish my protocol and start acquiring and analyzing data?
 - A: Before you engage in any activities that fall under the definition of "research" you must apply for, and receive, IRB approval.
- 6. Q: What definition of research should I be using?
 - A: Research is "...a systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge." Activities that fall into this category may include:
 - a. Collecting, compiling and analyzing data from computers, files or patients.
 - b. Analyzing clinical data to discern patterns.
 - c. Tracking data on different treatments or practices to compare results.
 - d. Providing information about patients to vendors, outside providers or institutions so they may compile, analyze or compare evaluations (even if you have shared information in the past).
 - e. Publishing or presenting information collected or analyzed in which KP member data is included.
- 7. Q: If I am unsure if I need IRB approval, who should I contact?
 - A: Please contact LaTrina B. Neal, Director, Human Research Protections and IRB Administrator, at 301-816-6572.
- 8. Q: What is HIPAA's "minimum necessary" requirement?
 - A: According to Health and Human Services, when using, disclosing or requesting PHI, reasonable efforts must be made to use, disclose or request only the minimum amount necessary for the intended purpose.
 - When a covered entity, such as KP, receives, requests or stores PHI, it must identify:
 - a. Those persons or classes of persons in the workforce (which includes employees, volunteers, trainees, contractors and employees of contractors) who need access to PHI to carry out their duties; and
 - b. The category or categories of PHI to which access is needed.

Based on these factors KP must establish appropriate conditions on access to PHI to ensure that:

- a. Only staff with a need for access to PHI has such access: and
- b. Staff shall only have access to the categories of PHI needed to carry out their assigned duties.
- 9. Q: What is Decedent PHI?
 - A: The HIPAA Privacy Rule protects the individually identifiable health information about a decedent (deceased person) for 50 years following the date of death of the individual. For more information, click here.